Skip to content

ET Stigma Response to Tremor Suppression

ET Stigma Response to Tremor Suppression With Focused Ultrasound Thalamotomy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07430761
Enrollment
220
Registered
2026-02-24
Start date
2025-01-01
Completion date
2027-08-30
Last updated
2026-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Action Tremor, Stigma, Social

Keywords

Essential tremor, stigma, thalamotomy, high intensity focused ultrasound

Brief summary

Essential Tremor (ET) is prevalent, affecting approximately 3% of the adult population. Involuntary shaking of the hands during action is a prominent feature, interfering with feeding and writing and other manual tasks. The involuntary movement is visible to observers, some of whom misinterpret the shakiness as manifestation of anxiety or instability, while some other observers attribute it to alcohol or drug use. The psychological effects of resulting stigma on quality of life for people with ET can rival the physical difficulties caused by the condition. For this study, we propose to measure 1 year after effective tremor suppression following thalamotomy with high intensity focused ultrasound changes from baseline in psychological distress and social dysfunction related to ET stigma, and to correlate change from baseline with improvement in functional status related to tremor and in objective measures of tremor severity. We hope to discover that ET stigma is largely reversible when tremor is effectively treated, and we aim to learn what degree of tremor suppression correlates with substantial psychological relief. We will also determine if ET stigma is predominantly helped by unilateral dominant-hand treatment, or if the second side treatment is necessary to accomplish most benefit.

Detailed description

Study procedures: Subjects will complete the following three surveys on two occasions i.e. at baseline, hours or days before thalamotomy, and again 12 months after the procedure (with a window of 11 to 18 months). Completing the three surveys takes approximately 5 minutes. 1. The ET-stigma distress scale which has 11 items each with 5 response options ranging from "strongly disagree" to "strongly agree" 2. the ET stigma dysfunction scale which has 5 items each with 3 response options ranging from "not at all or rarely" to "frequently" 3. the Tremor Disability Scale-Revised with 20 items each with 4 response options ranging from "no difficulty" to "cannot perform the task".

Interventions

PROCEDUREstereotactic thalamotomy with focused ultrasound

stereotactic thalamotomy with high intensity focused ultrasound, guided by four-tract tractography

Sponsors

University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* People with ET as diagnosed by a movement disorder neurologist * Tremor of sufficient severity and impact on quality of life so as to justify a lesional brain procedure * Competent to consent to undergoing high intensity focused ultrasound thalamotomy targeted by 4-tract tractography * Provide verbal informed consent to this study of ET stigma

Exclusion criteria

* Patient declines to participate in this observational study

Design outcomes

Primary

MeasureTime frameDescription
ET stigma psychological distresschange from baseline before thalamotomy to 12 months after thalamotomyPsychological distress related to other people's reaction to their tremor.
ET stigma social dysfunctionchange from baseline before thalamotomy to 12 months after thalamotomySocial avoidance and maladaptive behaviors related to other people's reaction to tremor.

Countries

United States

Contacts

CONTACTPadraig E O'Suilleabhain, MD
padraig.osuilleabhain@utsouthwestern.edu2146482943
CONTACTPadraig E O'Suilleabhain
2146482943
PRINCIPAL_INVESTIGATORPadraig E O'Suilleabhain, MD

University of Texas Southwestern Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026